Clinical trial · Interventional
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
A Phase I Trial of Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Lack of Funding
Summary
Brief summary (as posted)
The purpose of this study is to examine the use of activated T cells (ATCs) to assess the safety and tolerability of autologous activated T cells, as measured by the number of Grade 3 or higher toxicities, the number of serious adverse events, and treatment-related toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of overall survival, rate of progression-free survival, health-related quality of life parameters, overall response rate, immune response, and tumor stem cell antigen expression.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Activated T cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Activated T cells
- interventionNames
- Biological: Activated T cells
Primary outcomes (1)
- measure
- Number of Grade 3 or higher toxicities, number of serious adverse events, and the number of treatment-related toxicities to find the maximum tolerated dose
- timeFrame
- From start of study treatment until End of Study, an average of 2 months
- description
- Recorded and graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAEs) Version 5
Secondary outcomes (6)
- measure
- Overall Survival (OS)
- timeFrame
- From date of enrollment to date of death of any cause or withdrawal of consent, whichever came first. Assessed up to 3 years.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Recurrent glioblastoma * HLA-A1 and HLA-A2 positive * Complete resection of tumor Exclusion Criteria: * Clinically significant pulmonary, cardiac or other systemic disease * Presence of an acute infection requiring active treatment with antibiotics/antivirals; prophylactic administration is allowed. * Known human immunodeficiency virus positivity or acquired immunodeficiency syndrome related illness or other serious medical condition. * Known history of Hepatitis B or Hepatitis C * Allergy to Dimethyl sulfoxide (DMSO) * Allergy to gentamicin
References
Publications (0)
Data not yet available